West Pharma moving away from CMO biz; Catalent replacing bioreactors for biologics production;

> West Pharmaceutical ($WST) is sticking with its plan to transition away from contract manufacturing, eyeing long-term profits from proprietary drugs. Story

> Catalent has replaced all of the stainless-steel bioreactors at one of its biologics facilities with single-use devices, saying the change has increased speed, flexibility and cost efficiency. News

> Cardiac testing laboratory cardioCORE Lab has been acquired by CardioNet, a heart diagnostic firm, for $23.5 million. Release

> French CRO Quinten is rapidly growing thanks to novel approach to data mining, breaking trial data up into patient subgroups to better predict outcomes in future studies. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.